explore -WSS

explore

author：explore 2025-09-03 15:19:44 - browse：864

US Capitol - SOTU — Lawmakers in Congress have decided to punt efforts to reform how PBMs operate. BRENDAN SMIALOWSKI/AFP/Getty Images

WASHINGTON — Congress has abandoned its attempt to reform how pharmacy middlemen operate in an upcoming package to fund the federal government, 11 lobbyists and sources following the talks told STAT.

It’s a missed opportunity to pass one of the health care priorities that has attracted the most bipartisan interest and activity this Congress, though lawmakers could revive the negotiations on the issues in the future.

Reforming how pharmacy benefit managers operate has been a top lobbying priority for the pharmaceutical industry since Democrats passed a major package aimed at lowering the costs of medicines in 2022. Pharma and PBMs have taken up a very public battle on the airwaves.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： New menopause drug shows promise in relief for hot flashes

WSS

The nurse manager staffing crisis is hurting patients

Eight reasons why you should get an updated Covid vaccine

HHS names first

Massive project maps cells in human brain in unprecedented detail

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

How should state employee insurance handle Wegovy?

Wikipedia

explore

focus

Medicare details structure of new drug price negotiation program

Bernie Sanders bashes nonprofit hospitals over their tax breaks

BioMarin wins approval for gene therapy to treat hemophilia A

Risky weight loss products often used by teens globally, per study

As demand for Covid shots wanes, Moderna seeks its next success

STAT Readout Newsletter: Today in biotech, life science news

Peter Hotez and the public health issue of online harassment

What the Wegovy shortage looks like for doctors — and for patients

Hollywood unions extend contract negotiations for actors

Nick Jonas talks about managing diabetes along with his career

focus

How should state employee insurance handle Wegovy?

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Designating disabled people as health disparity population is crucial

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Biotech reporter’s notebook: A sunnier mood at JPM 2024

STAT Readout: Today's biotech news includes Sana and Amylyx

hotspot

explore

explore

leisure time